Amy Nicholas
Medical · Grapevine, TXNPI 1811983174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 28.9% of the total. 2025 is the largest year on record at $770, 3.9 times the $198 reported in 2021.
Across 114 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$638
- Sanofi$394
- Takeda Pharmaceuticals U.S.A., Inc.$215
- Grifols USA, LLC$140
- Kaleo, Inc.$131
- Sanofi-aventis U.S. LLC$108
- plus $579 from 12 others
What the payments were for
- Food & beverage$2,12396%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 35 | $638 |
| Sanofi | 19 | $394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $215 |
| Grifols USA, LLC | 7 | $140 |
| Kaleo, Inc. | 8 | $131 |
| Sanofi-aventis U.S. LLC | 3 | $108 |
| Novartis | 4 | $103 |
| CSL Behring | 4 | $92 |
| GSK | 6 | $91 |
| Optinose US, Inc. | 5 | $89 |
| AstraZeneca | 3 | $60 |
| Octapharma USA, Inc. | 1 | $32 |
| Pfizer | 2 | $32 |
| Amgen | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
| Galderma Laboratories, L.p. | 1 | $14 |
How this compares
$2,203 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 14 | $233 |
| Fluticasone Propionate | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other medical in Grapevine
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.